Details of the Drug

General Information of Drug (ID: DMC9O43)

Drug Name
Sevoflurane
Synonyms
Sevofluran; Sevoflurano; Sevofluranum; Sevofrane; Sevorane; Sojourn; Ultane; Fluoromethyl hexafluoroisopropyl ether; Bax 3084; F0691; MR6S4; MR_6S4; PC4681; Sevoflurano [INN-Spanish]; Sevofluranum [INN-Latin]; Ultane (TN); Sevoflurane (JAN/USAN/INN); Sevoflurane [USAN:INN:BAN:JAN]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1], [2]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 200.05
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 15 - 23 hours [3]
Metabolism
The drug is metabolized via the cytochrome P450 CYP2E1 to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2 [4]
Chemical Identifiers
Formula
C4H3F7O
IUPAC Name
1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
Canonical SMILES
C(OC(C(F)(F)F)C(F)(F)F)F
InChI
InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
InChIKey
DFEYYRMXOJXZRJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5206
ChEBI ID
CHEBI:9130
CAS Number
28523-86-6
DrugBank ID
DB01236
TTD ID
D0W6ZF
VARIDT ID
DR00465
INTEDE ID
DR1478

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Antagonist [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [7]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [8]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anaesthesia
ICD Disease Classification 9A78.6
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glutamate receptor AMPA (GRIA) DTT NO-GeName 1.79E-04 -0.69 -0.58
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 1.87E-04 -1.20E-01 -3.22E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.88E-01 -1.69E-05 -1.28E-04
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 2.02E-01 -2.49E-02 -1.81E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Sevoflurane (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Sevoflurane and Ivosidenib. Acute myeloid leukaemia [2A60] [50]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Midostaurin. Acute myeloid leukaemia [2A60] [51]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Arn-509. Acute myeloid leukaemia [2A60] [52]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Oliceridine. Acute pain [MG31] [51]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Ivabradine. Angina pectoris [BA40] [52]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Sevoflurane and Bepridil. Angina pectoris [BA40] [51]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Sevoflurane and Dronedarone. Angina pectoris [BA40] [51]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Sevoflurane and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [53]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Posaconazole. Aspergillosis [1F20] [51]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Levalbuterol. Asthma [CA23] [54]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Pirbuterol. Asthma [CA23] [55]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [52]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Retigabine. Behcet disease [4A62] [51]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Eribulin. Breast cancer [2C60-2C6Y] [51]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Bosutinib. Breast cancer [2C60-2C6Y] [52]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [56]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Olodaterol. Chronic obstructive pulmonary disease [CA22] [55]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Vilanterol. Chronic obstructive pulmonary disease [CA22] [54]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Indacaterol. Chronic obstructive pulmonary disease [CA22] [55]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Arformoterol. Chronic obstructive pulmonary disease [CA22] [55]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Probucol. Coronary atherosclerosis [BA80] [51]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Sevoflurane and Pasireotide. Cushing syndrome [5A70] [51]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Osilodrostat. Cushing syndrome [5A70] [51]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [51]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Deutetrabenazine. Dystonic disorder [8A02] [57]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Sevoflurane and Ingrezza. Dystonic disorder [8A02] [58]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Solifenacin. Functional bladder disorder [GC50] [51]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Sunitinib. Gastrointestinal stromal tumour [2B5B] [51]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [51]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [51]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [51]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Polyethylene glycol. Irritable bowel syndrome [DD91] [52]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Phenolphthalein. Irritable bowel syndrome [DD91] [51]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Sevoflurane and Crizotinib. Lung cancer [2C25] [59]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Sevoflurane and Ceritinib. Lung cancer [2C25] [51]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Sevoflurane and Osimertinib. Lung cancer [2C25] [60]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Sevoflurane and Selpercatinib. Lung cancer [2C25] [52]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Sevoflurane and Hydroxychloroquine. Malaria [1F40-1F45] [61]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [51]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Sevoflurane and Vemurafenib. Melanoma [2C30] [51]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and LGX818. Melanoma [2C30] [62]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Sevoflurane and Panobinostat. Multiple myeloma [2A83] [63]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Siponimod. Multiple sclerosis [8A40] [64]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Fingolimod. Multiple sclerosis [8A40] [51]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Sevoflurane and Ozanimod. Multiple sclerosis [8A40] [65]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Romidepsin. Mycosis fungoides [2B01] [51]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Sevoflurane and Nilotinib. Myeloproliferative neoplasm [2A20] [51]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Dasatinib. Myeloproliferative neoplasm [2A20] [51]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Entrectinib. Non-small cell lung cancer [2C25] [64]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Sevoflurane and Lofexidine. Opioid use disorder [6C43] [51]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Rucaparib. Ovarian cancer [2C73] [51]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Triclabendazole. Parasitic worm infestation [1F90] [51]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Pimavanserin. Parkinsonism [8A00] [66]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Sevoflurane and Macimorelin. Pituitary gland disorder [5A60-5A61] [67]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Sevoflurane and Lefamulin. Pneumonia [CA40] [68]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Degarelix. Prostate cancer [2C82] [52]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and ABIRATERONE. Prostate cancer [2C82] [52]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Enzalutamide. Prostate cancer [2C82] [52]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Relugolix. Prostate cancer [2C82] [52]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Levomepromazine. Psychotic disorder [6A20-6A25] [51]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Aripiprazole. Schizophrenia [6A20] [64]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Sevoflurane and Iloperidone. Schizophrenia [6A20] [51]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Paliperidone. Schizophrenia [6A20] [51]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Sevoflurane and Amisulpride. Schizophrenia [6A20] [69]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Asenapine. Schizophrenia [6A20] [51]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Sevoflurane and LEE011. Solid tumour/cancer [2A00-2F9Z] [51]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Sevoflurane and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [51]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [52]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Pitolisant. Somnolence [MG42] [51]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [51]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Lenvatinib. Thyroid cancer [2D10] [51]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Sevoflurane and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [64]
⏷ Show the Full List of 72 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7296).
2 Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
6 Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
7 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
8 Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
20 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
21 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
22 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
23 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
24 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
25 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
26 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
27 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
28 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
29 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
31 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
32 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
33 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
34 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
35 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
36 Drugs that may have potential CYP2B6 interactions.
37 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
38 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
39 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
40 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
41 Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
42 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
43 Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
44 Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
45 Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
46 Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
47 GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
48 Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
49 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
50 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
51 Canadian Pharmacists Association.
52 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
53 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
54 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
55 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
56 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
58 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
59 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
61 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
62 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
64 Cerner Multum, Inc. "Australian Product Information.".
65 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
66 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
67 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
68 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
69 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.